Cerity Partners
AXSM icon

Cerity Partners’s Axsome Therapeutics AXSM Stock Holding History

Cerity Partners’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$910K Sell
5,385
-4
-0.1% -$691 ﹤0.01% 1913
2025
Q4 		$984K Sell
5,389
-15
-0.3% -$2.09K ﹤0.01% 1735
2025
Q3 		$656K Sell
5,404
-248
-4% -$27.9K ﹤0.01% 1820
2025
Q2 		$590K Sell
5,652
-55
-1% -$5.82K ﹤0.01% 1777
2025
Q1 		$666K Buy
5,707
+766
+16% +$87.3K ﹤0.01% 1617
2024
Q4 		$419K Buy
4,941
+1,198
+32% +$110K ﹤0.01% 1865
2024
Q3 		$336K Buy
+3,743
New +$327K ﹤0.01% 1984

Other funds holding AXSM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Cerity Partners's AXSM Position: Q1 2026 in Review

Cerity Partners reduced its Axsome Therapeutics (AXSM) stake by 0.07% in Q1 2026, selling an estimated $691 and leaving 5,385 shares worth $910K. The position accounts for ﹤0.01% of the portfolio, ranked #1913.

Cerity Partners first reported a position in AXSM in Q3 2024 and has held it in 7 quarters since. The position peaked at $984K in Q4 2025. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

  • Cerity Partners held 5,385 shares of Axsome Therapeutics worth $910K as of Q1 2026.
  • Cerity Partners sold 4 Axsome Therapeutics shares in Q1 2026, an estimated $691.
  • Axsome Therapeutics made up ﹤0.01% of Cerity Partners's portfolio in Q1 2026, its #1913 holding.
  • Cerity Partners first reported a position in Axsome Therapeutics in Q3 2024 and has held it in 7 quarters since.
  • Cerity Partners's Axsome Therapeutics position peaked at $984K in Q4 2025.
  • 409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on Cerity Partners's 13F filing for Q1 2026, filed 15 May 2026.